BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 138.99 |
| Open | 143.48 |
| Bid | 143.59 x 100 |
| Ask | 144.60 x 100 |
| Day's Range | 141.78 - 146.22 |
| 52 Week Range | 126.97 - 266.67 |
| Volume | |
| Avg. Volume | 243,108 |
| Market Cap | 15.782B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -8.45 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 272.77 |
Business WireGlobal Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its broad hematology and solid tumor portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024.
Simply Wall St.With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
Key Insights Significantly high institutional ownership implies BeiGene's stock price is sensitive to their trading...
Business WireBeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., April 23, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has approved tislelizumab as a treatment for non-small cell lung cancer (NSCLC) across three indications, including first- and second-line use.
